Administering the HPV vaccine between ages 9 to 14 optimizes immunogenicity and long-term efficacy against cervical cancer. Early vaccination prior to HPV exposure reduces cancer risk significantly. Beyond 15, a three-dose schedule is required, with reduced efficacy in older age brackets. Timely intervention remains key.